Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 6.05 mg - capsule - excipient ingredients: colloidal anhydrous silica; gelatin; purified talc; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 30.25 mg - capsule - excipient ingredients: gelatin; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; purified talc; croscarmellose sodium; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - lenalidomide, quantity: 15 mg - capsule - excipient ingredients: povidone; mannitol; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; gelatin; titanium dioxide; indigo carmine; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm) lenalidomide is indicated for the treatment of multiple myeloma. ,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - lenalidomide, quantity: 15 mg - capsule - excipient ingredients: povidone; mannitol; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; gelatin; titanium dioxide; indigo carmine; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm) lenalidomide is indicated for the treatment of multiple myeloma. ,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 15 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - lenalidomide, quantity: 15 mg - capsule, hard - excipient ingredients: iron oxide yellow; gelatin; lactose; magnesium stearate; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; iron oxide black; brilliant blue fcf; iron oxide red; allura red ac; tartrazine; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; ethanol absolute; potassium hydroxide - multiple myeloma (mm) lenalidomide is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - lenalidomide, quantity: 15 mg - capsule, hard - excipient ingredients: gelatin; iron oxide black; lactose; microcrystalline cellulose; magnesium stearate; iron oxide yellow; croscarmellose sodium; allura red ac; iron oxide red; tartrazine; brilliant blue fcf; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; ethanol absolute; potassium hydroxide - multiple myeloma (mm) lenalidomide is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lenalidomide, quantity: 15 mg - capsule, hard - excipient ingredients: gelatin; croscarmellose sodium; microcrystalline cellulose; shellac; iron oxide black; magnesium stearate; potassium hydroxide; lactose monohydrate; titanium dioxide; indigo carmine aluminium lake; purified water - multiple myeloma (mm),lenalidomide ran is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide ran is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide ran is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lenalidomide, quantity: 15 mg - capsule, hard - excipient ingredients: iron oxide black; shellac; magnesium stearate; gelatin; microcrystalline cellulose; titanium dioxide; lactose monohydrate; croscarmellose sodium; potassium hydroxide; indigo carmine aluminium lake; purified water - multiple myeloma (mm),lenalidomide rbx is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide rbx is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide rbx is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lenalidomide, quantity: 15 mg - capsule, hard - excipient ingredients: croscarmellose sodium; iron oxide black; gelatin; lactose monohydrate; magnesium stearate; microcrystalline cellulose; titanium dioxide; shellac; potassium hydroxide; indigo carmine aluminium lake; purified water - multiple myeloma (mm),lenalidomide sun is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sun is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sun is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.